Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Is Medical Treatment Better at Lowering Bleeding-Caused Mortality than Angioplasty?

Post-discharge bleeding in patients admitted for acute coronary syndrome (ACS) is linked to higher all-cause mortality. However, this is the case for both patients who underwent angioplasty and those who were managed with medical treatment.

¿El tratamiento médico disminuye la mortalidad por sangrado vs la angioplastia?

These are interesting data, given that medical treatment is frequently preferred due to lower bleeding risk.

Speculation is based on the fact that, if the strategy were angioplasty, the bleeding would be more serious because patients would be receiving antiplatelet therapy and, if it had to be interrupted, the risk of thrombosis would also be high.

However, the prognosis for this unique population of patients with ACSs who receive medical treatment and subsequently bleed was almost unknown.

The objective of this paper recently published in J Am Coll Cardiol was to assess the association between post-discharge bleeding and mortality according to the index hospitalization strategy (angioplasty or medical treatment), and to contrast infarction vs. bleeding as a complication.


Read also: EuroPCR 2020 | Revascularization vs. Initial Medical Treatment in Chronic Patients.


A dataset of 4 large studies (APPRAISE-2, PLATO, TRACER, and TRILOGY ACS) was analyzed to establish the association between post-discharge bleeding (7 days post-ACS) and mortality.

Out of 45,011 total participants, 1,133 experienced bleeding and 2,149 died during follow-up.

The risk for mortality was significantly higher <30 days after bleeding (up to 15x higher), as well as between 30 days to 12 months (almost 3x higher) from the complication. This association between mortality and bleeding was consistent in participants treated with angioplasty or medical treatment (p for interaction = 0.240).


Read also: Virtual ACC 2020 | ISCHEMIA-CKD: Invasive Strategy vs. Medical Treatment in Higher Risk Patients.


The association between bleeding and mortality was similar to the association between infarction and mortality in both treatment strategies (p for interaction = 0.696).

Conclusion

Post-discharge bleeding in patients hospitalized for acute coronary syndrome is associated with increased all-cause mortality. Furthermore, the impact on the prognosis is similar for both treatment strategies (angioplasty vs. medical treatment). The impact on the prognosis of recurrent infarction is similar to that of bleeding.

Original Title: Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI.

Reference: Guillaume Marquis-Gravel et al. J Am Coll Cardiol 2020;76:162–71. https://doi.org/10.1016/j.jacc.2020.05.031.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...